Fitxers

666315.pdf (1.25 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-05-28

Llicència de publicació

cc-by (c) Cordero Coma, Miguel et al., 2014
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/113335

Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1155/2014/717598

Resum

Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy. Methods. Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients. Results. Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20-38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P - 0.009) and mean 1 mm central retinal thickness (317 versus 261.2 mu, P -0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed. Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis.

Matèries

Uveïtis, Oftalmologia

Matèries (anglès)

Uveitis, Ophthalmology

Citació

Col·leccions

Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Citació

CORDERO COMA, Miguel, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators of Inflammation. 2014. Vol. 2014. ISSN 0962-9351. [consulted: 27 of May of 2026]. Available at: https://hdl.handle.net/2445/113335

Exportar metadades

JSON - METS

Compartir registre